| Literature DB >> 30013720 |
Jan Borys1, Mateusz Maciejczyk2, Bożena Antonowicz3, Adam Krętowski4, Danuta Waszkiel5, Piotr Bortnik1, Katarzyna Czarniecka-Bargłowska1, Magdalena Kocisz5, Julita Szulimowska6, Marek Czajkowski7, Napoleon Waszkiewicz8, Anna Zalewska5.
Abstract
Due to the high biotolerance, favourable mechanical properties, and osseointegration ability, titanium is the basic biomaterial used in maxillofacial surgery. The passive layer of titanium dioxide on the surface of the implant effectively provides anticorrosive properties, but it can be damaged, resulting in the release of titanium ions to the surrounding tissues. The aim of our work was to evaluate the influence of Ti6Al4V titanium alloy on redox balance and oxidative damage in the periosteum surrounding the titanium miniplates and screws as well as in plasma and erythrocytes of patients with mandibular fractures. The study included 31 previously implanted patients (aged 21-29) treated for mandibular fractures and 31 healthy controls. We have demonstrated increased activity/concentration of antioxidants both in the mandibular periosteum and plasma/erythrocytes of patients with titanium mandibular fixations. However, increased concentrations of the products of oxidative protein and lipid modifications were only observed in the periosteum of the study group patients. The correlation between the products of oxidative modification of the mandible and antioxidants in plasma/erythrocytes suggests a relationship between the increase of oxidative damage at the implantation site and central redox disorders in patients with titanium miniplates and screws.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30013720 PMCID: PMC6022263 DOI: 10.1155/2018/3714725
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Clinical characteristics of patients with titanium mandibular fixations and healthy controls.
| Serum/plasma | Control group | Study group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Geometric mean | Lower 95% CI of mean | Upper 95% CI of mean | Mean | SD | Geometric mean | Lower 95% CI of mean | Upper 95% CI of mean | |
| WBC ×103/ | 7.530 | 1.958 | 7.278 | 6.841 | 8.219 | 6.917 | 1.709 | 6.756 | 6.315 | 13.232 |
| RBC ×106/ | 5.207 | 0.411 | 5.193 | 5.062 | 5.352 | 5.070 | 0.264 | 5.064 | 4.977 | 10.047 |
| HGB g/dL | 15.270 | 1.027 | 15.240 | 14.908 | 15.632 | 15.320 | 0.720 | 15.300 | 15.067 | 30.387 |
| HCT % | 45.230 | 2.630 | 45.160 | 44.304 | 46.156 | 45.550 | 2.123 | 45.510 | 44.803 | 90.353 |
| MCV fL | 87.140 | 3.817 | 87.070 | 85.796 | 88.484 | 89.630 | 3.549 | 89.570 | 88.381 | 178.011 |
| MCHC g/dL | 33.760 | 0.918 | 33.750 | 33.437 | 34.083 | 33.650 | 1.524 | 33.620 | 33.114 | 66.764 |
| PLT ×103/ | 230.700 | 43.800 | 227.100 | 215.282 | 246.118 | 228.300 | 23.380 | 227.300 | 220.070 | 448.370 |
| PT s | 12.230 | 0.624 | 12.220 | 12.010 | 12.450 | 11.660 | 0.699 | 11.640 | 11.414 | 23.074 |
| INR | 0.935 | 0.077 | 0.933 | 0.908 | 0.962 | 0.908 | 0.072 | 0.906 | 0.883 | 1.791 |
| APTT s | 27.640 | 1.468 | 27.610 | 27.123 | 28.157 | 26.780 | 3.809 | 26.550 | 25.439 | 52.219 |
| Na+ mmol/L | 140.700 | 1.890 | 140.700 | 140.035 | 141.365 | 139.800 | 1.184 | 139.800 | 139.383 | 279.183 |
| K+ mmol/L | 4.363 | 0.317 | 4.353 | 4.251 | 4.475 | 4.390 | 0.215 | 4.386 | 4.314 | 8.704 |
| CRP mg/L | 1.050 | 0.370 | 1.002 | 0.920 | 1.180 | 1.000 | 0.548 | 0.880 | 0.807 | 1.807 |
∗Statistical significance p < 0.05, study group versus control.
Enzymatic and nonenzymatic antioxidants, antioxidant/oxidant status, and oxidative damage in the mandible (Man) of patients with titanium mandibular fixations and healthy controls.
| Man | Control group | Study group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Geometric mean | Lower 95% CI of mean | Upper 95% CI of mean | Mean | SD | Geometric mean | Lower 95% CI of mean | Upper 95% CI of mean | |
| CAT nmol H2O2/min/mg protein | 1.435 | 0.349 | 0.973 | 1.312 | 2.747 | 0.605∗ | 0.139 | 0.272 | 0.556 | 1.160 |
| SOD mU/mg protein | 136.500 | 20.240 | 119.400 | 129.375 | 265.875 | 282.000∗ | 44.750 | 175.200 | 266.247 | 548.247 |
| GPx IU/mg protein | 0.024 | 0.003 | 0.022 | 0.022 | 0.046 | 0.027 | 0.006 | 0.025 | 0.025 | 0.052 |
| UA | 0.155 | 0.024 | 0.125 | 0.146 | 0.301 | 0.285∗ | 0.040 | 0.234 | 0.271 | 0.556 |
| GSH | 1.496 | 0.299 | 1.178 | 1.391 | 2.887 | 1.121 | 0.242 | 0.810 | 1.036 | 2.157 |
| TAC | 67.420 | 9.123 | 57.140 | 64.209 | 131.629 | 252.700∗ | 35.150 | 204.000 | 240.327 | 493.027 |
| TOS | 1.088 | 0.186 | 0.895 | 1.023 | 2.111 | 1.953 | 0.632 | 1.202 | 1.730 | 3.683 |
| OSI % | 1.956 | 0.406 | 1.441 | 1.813 | 3.769 | 1.188 | 0.337 | 1.340 | 1.069 | 2.257 |
| FRAP | 20.100 | 3.496 | 11.540 | 18.869 | 38.969 | 28.660∗ | 4.034 | 22.820 | 27.240 | 55.900 |
| AGE fluorescence/mg protein | 91.410 | 13.390 | 77.730 | 86.697 | 178.107 | 197.500∗ | 22.010 | 174.400 | 189.752 | 387.252 |
| AOPP | 1.911 | 0.242 | 1.743 | 1.826 | 3.737 | 2.607∗ | 0.246 | 2.318 | 2.521 | 5.128 |
| 4-HNE | 234.900 | 43.450 | 210.700 | 219.605 | 454.505 | 405.000∗ | 42.540 | 377.300 | 390.025 | 795.025 |
| 8-OHdG pg/mg protein | 52.340 | 8.200 | 46.890 | 49.454 | 101.794 | 71.160 | 11.740 | 64.010 | 67.027 | 138.187 |
| Total protein mg/mL | 3094.000 | 288.400 | 2964.000 | 2992.480 | 6086.480 | 1948.000∗ | 210.000 | 1145.000 | 1874.078 | 3822.078 |
4-HNE: 4-hydroxynonenal protein adducts; 8-OHdG: 8-hydroxydeoxyguanosine; AGE: advanced glycation end products; AOPP: advanced oxidation protein products; CAT: catalase; FRAP: ferric reducing ability of plasma; GPx: glutathione peroxidase; GSH: reduced glutathione; Man: mandible; OSI: oxidative stress index; SOD: superoxide dismutase-1; TAC: total antioxidant status; TOS: total oxidant status; UA: uric acid; ∗statistical significance p < 0.05, study group versus control.
Enzymatic and nonenzymatic antioxidants, antioxidant/oxidant status, and oxidative damage in the erythrocytes/plasma of patients with titanium mandibular fixations and healthy controls.
| Erythrocytes/plasma | Control group | Study group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Geometric mean | Lower 95% CI of mean | Upper 95% CI of mean | Mean | SD | Geometric mean | Lower 95% CI of mean | Upper 95% CI of mean | |
| CAT nmol H2O2/min/mg protein | 6.900 | 1.047 | 5.127 | 6.531 | 13.431 | 48.830∗ | 5.823 | 39.510 | 46.780 | 95.610 |
| SOD mU/mg protein | 153.600 | 7.930 | 149.600 | 150.809 | 304.409 | 154.800 | 11.270 | 145.500 | 150.833 | 305.633 |
| GPx IU/mg protein | 0.020 | 0.002 | 0.019 | 0.019 | 0.039 | 0.020 | 0.001 | 0.019 | 0.019 | 0.039 |
| UA | 0.658 | 0.011 | 0.656 | 0.654 | 1.312 | 0.733∗ | 0.012 | 0.730 | 0.729 | 1.462 |
| GSH | 0.687 | 0.178 | 0.517 | 0.625 | 1.312 | 0.463 | 0.044 | 0.410 | 0.447 | 0.910 |
| TAC | 49.570 | 7.384 | 44.020 | 46.971 | 96.541 | 37.680 | 6.483 | 26.780 | 35.398 | 73.078 |
| TOS | 0.629 | 0.186 | 0.508 | 0.564 | 1.193 | 0.382 | 0.055 | 0.316 | 0.363 | 0.745 |
| OSI % | 1.318 | 0.282 | 1.128 | 1.219 | 2.537 | 1.902 | 0.551 | 1.181 | 1.708 | 3.610 |
| FRAP | 13.580 | 3.186 | 11.750 | 12.458 | 26.038 | 10.990 | 3.239 | 6.285 | 9.850 | 20.840 |
| AGE fluorescence/mg protein | 526.000 | 30.420 | 507.700 | 515.292 | 1041.292 | 603.500 | 180.100 | 365.200 | 540.103 | 1143.603 |
| AOPP umol/mg protein | 0.497 | 0.049 | 0.452 | 0.479 | 0.976 | 0.506 | 0.054 | 0.439 | 0.487 | 0.994 |
| 4-HNE | 80.890 | 12.860 | 70.980 | 76.363 | 157.253 | 108.500 | 17.570 | 93.980 | 102.315 | 210.815 |
| 8-OHdG pg/mg protein | 27.350 | 4.247 | 21.110 | 25.855 | 53.205 | 32.750∗ | 5.534 | 27.510 | 30.802 | 63.552 |
| Total protein mg/mL | 4444.000 | 109.400 | 4416.000 | 4405.490 | 8849.490 | 3445.000∗ | 213.300 | 2712.000 | 3369.916 | 6814.916 |
4-HNE: 4-hydroxynonenal protein adducts; 8-OHdG: 8-hydroxydeoxyguanosine; AGE: advanced glycation end products; AOPP: advanced oxidation protein products; CAT: catalase; FRAP: ferric reducing ability of plasma; GPx: glutathione peroxidase; GSH: reduced glutathione; OSI: oxidative stress index; SOD: superoxide dismutase-1; TAC: total antioxidant status; TOS: total oxidant status; UA: uric acid; ∗statistical significance p < 0.05, study group versus control.
Correlations of redox biomarkers in control group and patients with titanium mandibular fixations.
|
|
| ||
|---|---|---|---|
|
| |||
| TOS Man | OSI Man | 0.551 | 0.033 |
| TAC Man | UA plasma | 0.425 | 0.043 |
| GPx erythrocytes | FRAP plasma | 0.737 | 0.037 |
| TAC plasma | GSH plasma | 0.608 | 0.003 |
| 8-OHdG plasma | AOPP plasma | 0.559 | 0.047 |
|
| |||
| UA Man | FRAP Man | 0.519 | 0.019 |
| TAC Man | AGE Man | 0.450 | 0.031 |
| 4-HNE Man | OSI Man | 0.592 | 0.043 |
| 8-OHdG Man | AGE Man | 0.883 | 0.000 |
| TOS Man | OSI Man | 0.567 | 0.034 |
| AGE Man | GPx erythrocytes | 0.574 | 0.025 |
| TOS Man | CAT erythrocytes | 0.515 | 0.043 |
| 8-OHdG Man | GPx erythrocytes | 0.781 | 0.002 |
| TAC Man | UA plasma | 0.425 | 0.043 |
| 4-HNE Man | GSH plasma | 0.662 | 0.019 |
| GSH Man | GSH plasma | 0.417 | 0.048 |
| SOD erythrocytes | AGE plasma | 0.470 | 0.020 |
| TAC plasma | AOPP plasma | 0.695 | 0.000 |
| TOS plasma | AOPP plasma | 0.529 | 0.000 |
| TOS plasma | GSH plasma | 0.645 | 0.002 |
| 8-OHdG plasma | GSH plasma | 0.589 | 0.044 |
4-HNE: 4-hydroxynonenal protein adducts; 8-OHdG: 8-hydroxydeoxyguanosine; AGE: advanced glycation end products; AOPP: advanced oxidation protein products; CAT: catalase; FRAP: ferric reducing ability of plasma; GPx: glutathione peroxidase; GSH: reduced glutathione; Man: mandible; OSI: oxidative stress index; SOD: superoxide dismutase-1; TAC: total antioxidant status; TOS: total oxidant status; UA: uric acid.